Form 8-K - Current report:
SEC Accession No. 0001104659-24-064247
Filing Date
2024-05-22
Accepted
2024-05-22 16:05:33
Documents
14
Period of Report
2024-05-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2415024d1_8k.htm   iXBRL 8-K 29565
2 EXHIBIT 4.1 tm2415024d1_ex4-1.htm EX-4.1 14607
  Complete submission text file 0001104659-24-064247.txt   214726

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA enzn-20240516.xsd EX-101.SCH 3006
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE enzn-20240516_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE enzn-20240516_pre.xml EX-101.PRE 22353
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2415024d1_8k_htm.xml XML 3247
Mailing Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016
Business Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016 732-980-4500
ENZON PHARMACEUTICALS, INC. (Filer) CIK: 0000727510 (see all company filings)

EIN.: 222372868 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-12957 | Film No.: 24973239
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)